| Assessment Status |
Assessment process complete |
| HTA ID |
- |
| Drug |
Stiripentol |
| Brand |
Diacomit® |
| Indication |
In conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet’s syndrome) whose seizures are not adequately controlled with clobazam and valproate |
| Rapid review commissioned |
06/07/2017 |
| Rapid review completed |
10/08/2017 |
| Rapid review outcome |
A Full pharmacoeconomic assessment is recommended |
| Full pharmacoeconomic assessment commissioned by HSE |
04/09/2017 |
| Pre-submission consultation with Applicant |
15/01/2018 |
| Full submission received from Applicant |
06/07/2018 |
| Preliminary review sent to Applicant |
19/12/2018 |
| NCPE assessment re-commenced |
21/12/2018 |
| Follow-up to preliminary review sent to Applicant |
04/02/2019 |
| NCPE assessment re-commenced |
06/02/2019 |
| Factual accuracy sent to Applicant |
14/03/2019 |
| NCPE assessment re-commenced |
29/03/2019 |
| NCPE assessment completed |
03/05/2019 |
| NCPE assessment outcome |
The NCPE recommends that stiripentol (Diacomit®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013. |
